Research programme: anti-CMV therapy - Kemin Pharma

Drug Profile

Research programme: anti-CMV therapy - Kemin Pharma

Alternative Names: KPE00001015; KPE00001116; KPE1015; KPE1116

Latest Information Update: 23 Sep 2008

Price : $50

At a glance

  • Originator Kemin Pharma
  • Class Antivirals; Carbohydrates
  • Mechanism of Action Cytomegalovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 23 Sep 2008 Discontinued - Preclinical for Cytomegalovirus infections in Belgium (unspecified route)
  • 17 Mar 2008 Preclinical development is ongoing
  • 13 Jan 2005 Lead compounds from this programme are available for licensing worldwide (http://www.kemin.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top